CN100415259C - Medicine for treating coronary heart disease and preparation thereof - Google Patents
Medicine for treating coronary heart disease and preparation thereof Download PDFInfo
- Publication number
- CN100415259C CN100415259C CNB2005100167551A CN200510016755A CN100415259C CN 100415259 C CN100415259 C CN 100415259C CN B2005100167551 A CNB2005100167551 A CN B2005100167551A CN 200510016755 A CN200510016755 A CN 200510016755A CN 100415259 C CN100415259 C CN 100415259C
- Authority
- CN
- China
- Prior art keywords
- medicine
- heart disease
- preparation
- coronary heart
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a medicine for treating coronary disease, particularly to a Chinese parent medicine with Chinese herbal medicine used as raw material. The present invention also relates to a preparation method of the medicine. The medicine uses chuanxiong rhizome, cattail pollen, Trogopterus Dung and borneol as main raw materials. Four kinds of auxiliary medicine such as red sage root, giant knotweed rhizome, notoginseng and leech are added to the main raw materials as required. The materials are respectively dried, crushed or extracted by a solvent based on different characteristics of all kinds of Chinese herbal medicine. Powder preparation, capsule preparation and pill preparation are then formed proportionally. The present invention has the functions ofpromoting blood circulation and removing blood stasis, and promoting qi circulation and removing obstruction in the collateral channels. The present invention has obvious therapeutic effects on coronary disease and angina pectoris.
Description
Technical field
The present invention relates to a kind of medicine for the treatment of coronary heart disease, specifically a kind of is the Chinese patent medicine of feedstock production with the Chinese herbal medicine.The invention still further relates to the preparation method of this medicine.
Background technology
Coronary heart disease is the abbreviation of coronary atherosclerotic heart disease, is the common frdquently encountered disease of serious harm human health, and mortality rate is very high.Coronary heart disease comprises 5 types of angina pectoris, myocardial infarction, latent coronary heart disease, ischemic cardiomyopathy type coronary heart disease and sudden death coronary heart diseases.
The medicine for the treatment of at present coronary heart disease clinically has a lot, the Western medicine side effect of wherein treating coronary heart disease greatly and also pharmacological action single, the Chinese medicine effect of coronary heart disease is undesirable, curative effect is slower and be used for the treatment of at present.Therefore at present clinically still demand have definite curative effect and the Chinese herbal medicine combination preparation rapidly of taking effect is used for the treatment of coronary heart disease.
Both at home and abroad to the primary disease Drug therapy, run into following thorny problem at present.
1, western medicine is long the course of treatment, and the price height easily causes the infringement to normal organ, the individual drug weak curative effect.
2, western medicine exists late result relatively poor relatively, the problem that need take medicine for a long time.
3, also there is the unfavorable problem of curative effect in other Chinese medicine compositions.
Summary of the invention
Order of the present invention is to provide a kind of Chinese patent medicine that is raw material with the Chinese herbal medicine, has the treatment coronary heart disease of blood circulation promoting and blood stasis dispelling, promoting of the circulation of QI and removing the obstruction in the collaterals effect.
Another object of the present invention provides the preparation method of this coronary heart disease treatment agent.
Solution of the present invention is based on understanding and the Therapeutic Principle of motherland's medical science to incidence of coronary heart disease mechanism, newly achieve with reference to modern pharmacological research, in conjunction with clinical data for many years, from motherland's medicine treasure-house, filter out the pure natural medical of blood circulation promoting and blood stasis dispelling, promoting of the circulation of QI and removing the obstruction in the collaterals, according to the theory of Chinese medical science prescription, extract the medicine elite by the modern science and technology means.Make its performance coronary artery dilator, promote the CC circulation, improve the myocardial cell Nutrition and Metabolism, allevating angina pectoris outbreak, the complication of minimizing and treatment coronary heart disease, the effect that improves patient's life quality.
Medicine of the present invention is the medicament of being made by the following weight proportion raw material:
Rhizoma Chuanxiong 2-10 part; Pollen Typhae 2-10 part; Oletum Trogopterori 2-10 part; Borneolum Syntheticum 1-8 part.
Wherein the weight proportion of each raw material is:
5 parts of Rhizoma Chuanxiongs; 4 parts of Pollen Typhaes; 5 parts of Oletum Trogopteroris; 2 parts of Borneolum Syntheticums.
Described medicine can increase Radix Salviae Miltiorrhizae, two kinds of ancillary drugs of Rhizoma Polygoni Cuspidati, and its weight proportion is: Rhizoma Chuanxiong 2-10 part; Pollen Typhae 2-10 part; Oletum Trogopterori 2-10 part; Borneolum Syntheticum 1-8 part; Radix Salviae Miltiorrhizae 3-10 part; Rhizoma Polygoni Cuspidati 3-10 part.
Described medicine can also increase Radix Salviae Miltiorrhizae, Rhizoma Polygoni Cuspidati, three kinds of ancillary drugs of Radix Notoginseng, and its weight proportion is: Rhizoma Chuanxiong 2-10 part; Pollen Typhae 2-10 part; Oletum Trogopterori 2-10 part; Borneolum Syntheticum 1-8 part; Radix Salviae Miltiorrhizae 3-10 part; Rhizoma Polygoni Cuspidati 3-10 part; Radix Notoginseng 1-8 part.
Described medicine can also increase Radix Salviae Miltiorrhizae, Rhizoma Polygoni Cuspidati, Radix Notoginseng, four kinds of ancillary drugs of Hirudo, and its weight proportion is: Rhizoma Chuanxiong 2-10 part; Pollen Typhae 2-10 part; Oletum Trogopterori 2-10 part; Borneolum Syntheticum 1-8 part; Radix Salviae Miltiorrhizae 3-10 part; Rhizoma Polygoni Cuspidati 3-10 part; Radix Notoginseng 1-8 part; Hirudo 1-8 part.
Active component in the pharmaceutical composition of the present invention can be the Chinese crude drug powder or the extract of said ratio, and optional water of extract or ethanol are solvent, preferred alcohol, and concentration is 95%, extracting method is conventional decocting method.
Above-mentioned each component is made production method of the present invention:
1, earlier Rhizoma Chuanxiong, Pollen Typhae, Oletum Trogopterori or ancillary drug Radix Salviae Miltiorrhizae, Rhizoma Polygoni Cuspidati decocting are extracted medicinal liquid and be condensed into extractum.
2, Borneolum Syntheticum or ancillary drug Radix Notoginseng, Hirudo are ground into 120 order fine powders after air-dry.
3, with after 1 and 2 step gained fine powders and the extractum mixing, oven dry is ground into 120 order fine powders, with gained fine powder fill capsule; Also fine powder can be added a small amount of excipient (dextrin, sugar) and make fill capsule behind the granule with granulator; Also can add processed with honey and become pill; Also can directly pack and make powder for clinical use.
4, constituent of the present invention also can be passed through other extracting method effective component extractings, makes various dosage forms and is applied to clinical.
An important feature of the present invention is to have one's ideas straightened out the Pollen Typhae, Oletum Trogopterori, Rhizoma Chuanxiong, Borneolum Syntheticum of effect as the principal agent in the treatment coronary heart disease prescription with having blood circulation promoting and blood stasis dispelling, circulation of qi promoting.
Clinical drug of the present invention uses the result to show that following advantage is arranged:
1, the selected medicine of the present invention is pure natural medical, and each component meets the pharmaceutical control law regulation, utilizes the comprehensive function treatment coronary heart disease of the Chinese medicine of respectively distinguishing the flavor of nontoxic to human body.
2, taking convenience of the present invention meets the national health law regulation.
3, relief of symptoms rapidly after patients with coronary heart disease uses, and late result is preferably arranged.
For showing the therapeutic effect of medicine of the present invention to coronary heart disease, the present invention is through the clinical observation of 60 routine systems, and selects 60 examples to be matched group, and the observation situation is as follows:
1, clinical data:
This group data is taken from my clinical observation, totally 60 examples, and other establishes matched group 60 examples.All be diagnosed as coronary heart disease, all have angina pectoris history of repeated attack and ischemic ST-T to change, be twinge of light moderate pareordia or squeezing sample pain, the standard that diagnostic criteria is formulated according in JIUYUE, 1979 Shanghai cardiovascular meeting.60 examples are organized in treatment, wherein male 31 examples, women 29 examples; 40～70 years old age, average 51 years old; Belong to stable angina pectoris person's 21 examples, unstable angina pectoris person's 39 examples; Merge hyperlipidemia person's 47 examples, merge arrhythmia person's 27 examples, complicated hypertension person 34 examples, complication with diabetes person 14 examples.Matched group 60 examples, wherein male 29 examples, women 31 examples; 42～79 years old age, average 53 years old; Belong to stable angina pectoris person's 20 examples, unstable angina pectoris person's 40 examples; Merge hyperlipidemia person's 45 examples, merge arrhythmia person's 25 examples, complicated hypertension person 35 examples, complication with diabetes person 16 examples.
2, Therapeutic Method and observation index:
2.1 Therapeutic Method: the treatment group is taken medicine of the present invention, instructions of taking, each 2 oral, every day three times, 15 days is a course of treatment.The each 10mg of the oral isosorbide 5-mono-nitrate fat of matched group, every day 3 times, 15 days is a course of treatment.
2.2 criterion of therapeutical effect: revise the angina pectoris symptom curative effect determinate standard according to national prevention and treatment in Chinese and western coronary heart disease, angina pectoris, arrhythmia research forum in 1979.
3, efficacy analysis:
3.1 treatment curative effect to treat angina pectoris: treatment group produce effects 26 examples (43.3%), improve 31 examples (51.7%), invalid substantially 3 examples (5%) increase the weight of 0 example, and total effective rate is 95.00%.Matched group produce effects 13 examples (21.67%) are improved 26 examples (43.33%), and invalid substantially 21 examples (35%) increase the weight of 0 example, total effective rate 65.00%.Two groups of curative effects are learned processing by statistics, and difference has significance (P＜0.01), illustrate that treatment group treatment angina pectoris effect is better than matched group.Unstable angina pectoris does not have myocardium infarction generation in the therapeutic process.
3.2 the electrocardiogram ischemic ST-T changes the result: treatment group produce effects 22 examples (36.67), improve 24 examples (40%), there are not 14 examples (23.33%) of change, increase the weight of 0 example, total effective rate 76.67.Matched group electrocardiogram produce effects 16 examples (26.67%) are improved 13 examples (21.66%), do not have 31 examples (51.67%) of change, increase the weight of 0 example, total effective rate 48.33%.Two groups of results learn processing by statistics, and difference has significance (P＜0.01), illustrate that treatment group electrocardiogram improves effective percentage and is significantly higher than matched group.
4, know from experience: treat coronary heart disease at present and take herbal treatment more, have certain advantage, we think that this medicine is a kind of promising treatment treating coronary heart disease and angina pectoris, all has curative effect preferably to clinical symptoms and the electrocardiogram that improves angina pectoris.
The specific embodiment
Embodiment 1:
Take by weighing raw material by following proportioning: Rhizoma Chuanxiong 5kg; Pollen Typhae 4kg; Oletum Trogopterori 5kg; Borneolum Syntheticum 2kg.Production method is as follows: earlier with Rhizoma Chuanxiong, and Pollen Typhae, the Oletum Trogopterori decocting extracts medicinal liquid and is condensed into extractum, and Borneolum Syntheticum powder is broken to 120 order fine powders, and fine powder is broken into 120 order fine powders with extractum mixing after bake dry powder.With last gained fine powder fill capsule, every heavy 0.3g.Also fine powder can be added a small amount of excipient (dextrin, sugar) and make fill capsule behind the granule with granulator; Also can add processed with honey and become pill; Also can directly pack and make powder for clinical use.
Embodiment 2:
Take by weighing raw material Rhizoma Chuanxiong 5kg by following proportioning; Pollen Typhae 4kg; Oletum Trogopterori 5kg; Borneolum Syntheticum 2kg Radix Salviae Miltiorrhizae 5kg; Rhizoma Polygoni Cuspidati 5kg.Production method is as follows: earlier with Rhizoma Chuanxiong, and Pollen Typhae, Oletum Trogopterori, Radix Salviae Miltiorrhizae, the Rhizoma Polygoni Cuspidati decocting extracts medicinal liquid and is condensed into extractum, and Borneolum Syntheticum is pulverized 120 order fine powders, and fine powder is broken into 120 order fine powders with extractum mixing after bake dry powder.Other preparation process are with embodiment 1.
Embodiment 3:
Take by weighing raw material by following proportioning: Rhizoma Chuanxiong 5kg; Pollen Typhae 4kg; Oletum Trogopterori 5kg; Borneolum Syntheticum 2kg; Radix Salviae Miltiorrhizae 5kg; Rhizoma Polygoni Cuspidati 5kg; Radix Notoginseng 3kg.Production method is as follows: earlier with Rhizoma Chuanxiong, and Pollen Typhae, Oletum Trogopterori, Radix Salviae Miltiorrhizae, the Rhizoma Polygoni Cuspidati decocting extracts medicinal liquid and is condensed into extractum, and Borneolum Syntheticum, Radix Notoginseng powder are broken to 120 order fine powders, and fine powder is broken into 120 order fine powders with extractum mixing after bake dry powder.Other preparation process are with embodiment 1.
Embodiment 4:
Take by weighing raw material by following proportioning: Rhizoma Chuanxiong 5kg; Pollen Typhae 4kg; Oletum Trogopterori 5kg; Borneolum Syntheticum 2kg; Radix Salviae Miltiorrhizae 5kg; Rhizoma Polygoni Cuspidati 5kg; Radix Notoginseng 3kg; Hirudo 1.2kg.Production method is as follows: earlier with Rhizoma Chuanxiong, and Pollen Typhae, Oletum Trogopterori, Radix Salviae Miltiorrhizae, the Rhizoma Polygoni Cuspidati decocting extracts medicinal liquid and is condensed into extractum, and Borneolum Syntheticum, Radix Notoginseng, Hirudo powder are broken to 120 order fine powders, and fine powder is broken into 120 order fine powders with extractum mixing after bake dry powder.Other preparation process are with embodiment 1.
Constituent of the present invention also can be passed through other extracting method effective component extractings, makes various dosage forms and is applied to clinical.
Claims (3)
1. treat treating coronary heart disease and angina pectoris for one kind, it is characterized in that: medicine of the present invention is the medicament of being made by following raw materials by weight proportions:
Rhizoma Chuanxiong 2-10 part; Pollen Typhae 2-10 part; Oletum Trogopterori 2-10 part; Borneolum Syntheticum 1-8 part; Radix Salviae Miltiorrhizae 3-10 part; Rhizoma Polygoni Cuspidati 3-10 part; Radix Notoginseng 1-8 part.
2. treatment treating coronary heart disease and angina pectoris according to claim 1 is characterized in that: described medicament is capsule, pill or powder.
3. the preparation method of treatment treating coronary heart disease and angina pectoris according to claim 2 is characterized in that: the preparation method of described capsule, pill or powder is as follows:
1., earlier Rhizoma Chuanxiong, Pollen Typhae, Oletum Trogopterori, Radix Salviae Miltiorrhizae, Rhizoma Polygoni Cuspidati decocting are extracted medicinal liquid and be condensed into extractum;
2., Borneolum Syntheticum, Radix Notoginseng are ground into 120 order fine powders after air-dry;
3., will be 1. and 2. go on foot gained fine powder and extractum and mix after, oven dry is ground into 120 order fine powders
4., will be 3. in gained fine powder fill capsule, or fine powder added a small amount of dextrin, sugar as excipient, make fill capsule behind the granule with granulator; Or add processed with honey and become pill; Or directly powder is made in pack.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100167551A CN100415259C (en) | 2005-04-25 | 2005-04-25 | Medicine for treating coronary heart disease and preparation thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100167551A CN100415259C (en) | 2005-04-25 | 2005-04-25 | Medicine for treating coronary heart disease and preparation thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1853696A CN1853696A (en) | 2006-11-01 |
| CN100415259C true CN100415259C (en) | 2008-09-03 |
Family
ID=37194348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100167551A Expired - Fee Related CN100415259C (en) | 2005-04-25 | 2005-04-25 | Medicine for treating coronary heart disease and preparation thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100415259C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101084959B (en) * | 2006-06-08 | 2011-06-08 | 天津天士力制药股份有限公司 | Traditional Chinese medicinal composition containing ligusticum wallichii, notoginseng and borneol or storax and preparation thereof |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103550428B (en) * | 2013-10-24 | 2015-08-26 | 江海艳 | One treats anginal medicine for external use |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1334121A (en) * | 2001-08-31 | 2002-02-06 | 石家庄以岭药业有限公司 | Medicinal composition for restoring cardiac collaterals and its application |
| CN1557467A (en) * | 2004-02-09 | 2004-12-29 | 周宝义 | Extraction and concentration combined pure Chinese medicinal preparation for treating cardiovascular diseases |
-
2005
- 2005-04-25 CN CNB2005100167551A patent/CN100415259C/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1334121A (en) * | 2001-08-31 | 2002-02-06 | 石家庄以岭药业有限公司 | Medicinal composition for restoring cardiac collaterals and its application |
| CN1557467A (en) * | 2004-02-09 | 2004-12-29 | 周宝义 | Extraction and concentration combined pure Chinese medicinal preparation for treating cardiovascular diseases |
Non-Patent Citations (2)
| Title |
|---|
| 与血液流变相关的中药临床应用浅谈. 丁学成.黑龙江中医药，第1994年卷第2期. 1994 |
| 与血液流变相关的中药临床应用浅谈. 丁学成.黑龙江中医药，第1994年卷第2期. 1994 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101084959B (en) * | 2006-06-08 | 2011-06-08 | 天津天士力制药股份有限公司 | Traditional Chinese medicinal composition containing ligusticum wallichii, notoginseng and borneol or storax and preparation thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1853696A (en) | 2006-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103083531B (en) | Drug for treating diabetes | |
| CN103386022A (en) | Chinese medicine composition for treating tuberculous pleurisy | |
| CN101584796B (en) | Application of traditional Chinese medicine composition in preparing medicament for treating melancholia | |
| CN100415259C (en) | Medicine for treating coronary heart disease and preparation thereof | |
| CN1173726C (en) | Medicine for curing malignant turnor and its preparation method | |
| CN100398139C (en) | Traditional Chinese Medicinal formulation for treating coronary heart disease and preparation method thereof | |
| CN1792372A (en) | Traditional Chinese medicine prepn. for treating diabetes | |
| CN102552520A (en) | Blood circulation-promoting and pain-stopping medicament for treating chest stuffiness and pains and preparation process and application thereof | |
| CN103182025B (en) | Traditional Chinese medicine composition for treating bradyarrhythmia, and application thereof | |
| CN108743885A (en) | A kind of Chinese medicine and preparation method thereof for treating Diabetic Macrovascular Complications | |
| CN108635457A (en) | A kind of Chinese medicine composition and the preparation method and application thereof for treating constipation | |
| CN103285107A (en) | Alcoholic hepatitis treatment Kazakh traditional drug composition and preparation method thereof | |
| CN103127358B (en) | Traditional Chinese medicine composition for treating rheumatoid arthritis and preparation method | |
| CN102836320B (en) | Chinese medicinal pill for treating tachyarrhythmia | |
| CN101406495B (en) | Medicament for mainly curing cardiovascular disease | |
| CN102188548A (en) | Medicinal compositions for treating psoriasis and preparation method thereof | |
| CN102085244B (en) | Chinese patent medicine for treating digestive system diseases | |
| CN101385810B (en) | Traditional Chinese medicine composition containing chinemys reevesii for treating dermatomyositis and preparation thereof | |
| CN101612233B (en) | Chinese medicine preparation for detumescence and analgesia | |
| CN1850157B (en) | Health-care for resisting hyperplasia of mammary glands | |
| CN1954847A (en) | Medicine for treating psoriasis | |
| CN103705703B (en) | Traditional Chinese medicine for treating cardiovascular and cerebrovascular diseases | |
| CN104001077A (en) | Traditional Chinese medicine composition for treating urinary tract infection and application thereof | |
| CN103989716B (en) | Plant extract product for treating osteoporosis, and applications thereof for preparation of medicines or healthcare products | |
| CN116889589A (en) | Chinese herbal compound preparation for treating sepsis ARDS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080903 Termination date: 20140425 |